QS-21: a water-soluble triterpene glycoside adjuvant

Bibliography

• NEWMAN MJ, POWELL MF: Immunologicalandformu-lationdesignconsiderationforsubunitvaccines.In Vaccine Design: The Subunit and Adjuvant Approach.Pow-ell MF, Newman MJ (Eds.), Plenum Press, New York, USA (1995) :1–42.
   Google Scholar
• DONNELLY JJ, ULMER JB, SHIVER JW, LIU MA: DNAvac-cines.Ann. Rev. Immunol.(1997) 15:617–648.
   PubMed Web of Science ®Google Scholar
• GREGORIADIS G: Geneticvaccines:strategiesforopti-mization.Pharm. Res.(1998) 15(5):661–670.
   Google Scholar
• GUPTA RK, ROST BE, RELYVELD E, SIBER GR: Adjuvantpropertiesofaluminumandcalciumcompounds.In Vaccine Design: The Subunit and Adjuvant Approach.Pow-ell MF, Newman MJ (Eds.), Plenum Press, New York, USA (1995):229–248.
   Google Scholar
• ALLISON AC: Themodeofactionofimmunologicalad-juvants.In Modulation of the Immune Response to Vaccine Antigens. Dev. Biol. Standards.Brown F, Haaheim LR (Eds.), Karger, Basel, Switzerland (1998):3–11.
   Google Scholar
• JOHNSON AG: Molecularadjuvantsandimmunomodu-lators:newapproachestoimmunization.Clin. Micro-bic)]. Rev.(1994) 7(3):277–289.
   Google Scholar
• GUPTA RK, SIBER GR: Adjuvantsforhumanvaccines:currentstatus,problemsandfutureprospects.Vaccine(1995) 13(14) :1263–1276.
   Google Scholar
• TOMAI MA, SOLEM LE, JOHNSON AG, RIBI E: Theadju-vant properties of a nontoxic monophosphoryl lipid A inhyporesponsiveandagingmice.J. Biol. Response Mod.(1987) 6(2):99–107.
   Google Scholar
• SASAKI S, TSUJI T, HAMAJIMA K et al.:Monophosphoryllipid A enhances both humoral and cell-mediated im-mune responses to DNA vaccination against human immunodeficiencyvirustype1.Infect. Immun.(1997) 65(9):3520–3528.
   Google Scholar
• SASAKI S, SUMINO K, HAMAJIMA K et al.:Inductionofsystemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine for-mulatedwithQS-21saponinadjuvantviaintramuscu-larandintranasalroutes.J. Virol.(1998) 72(6):4931–4939.
   Google Scholar
• •First report of QS-21 as an adjuvant with a DNA vaccine.
   Google Scholar
• FLEBBE LM, BRALEY-MULLEN H: Immunopotentiatingeffects of the adjuvants SGP and Quil A. I. Antibody re-sponses to T-dependent and T-independent antigens. Immunol(1986) 99(0:119–127.
   Google Scholar
• FLEBBE LM, BRALEY-MULLEN H: Immunopotentiationby SGP and Quil A. II. Identification of responding cell populations.Cell. Immunol(1986) 99(0:128–139.
   PubMedGoogle Scholar
• HOLMGREN J, LYCKE N, CZERKINSKY C: Choleratoxinand cholera B subunit as oral-mucosal adjuvant and antigenvectorsystems.Vaccine(1993) 11(12):1179–1184.
   PubMed Web of Science ®Google Scholar
• BAQAR S, BOURGEOIS AL, SCHULTHEISS PJ et al.Safety and immunogenicity of a prototype oral whole-cell killedCampylobactervaccineadministeredwithamu-cosaladjuvantinnon-humanprimates.Vaccine(1994) 13(1)22–28.
   Google Scholar
• OTT G, BARCHFELD GL, CHERNOFF D et al:MF59.De-sign and evaluation of a safe and potent adjuvant for humanvaccines.Pharm. Biotechnol.(1995) 6:277–296.
   Google Scholar
• ULRICH JT, MYERS KR: MonophosphoryllipidAasanadjuvant.Pastexperiencesandnewdirections.Pharm. Biotechnol.(1995) 6:495–524.
   PubMedGoogle Scholar
• DALSGAARD K: Astudyoftheisolationandcharacteri-zation of the saponin Quil A. Evaluation of its adjuvant activity, with a special reference to the application in the vaccination of cattle against foot-and-mouth dis-ease.Acta Vet. Scand.(1978) 69(Suppl.):7–40.
   Google Scholar
• KENSIL CR, PATEL U, LENNICK M, MARCIANI D: Separa-tion and characterization of saponins with adjuvant activityfromQuillajasaponariaMolinacortex.J.Im-munol(1991) 146(2):431–437.
   Google Scholar
• ••First published report on isolation and adjuvant activity ofQS-21.
   Google Scholar
• JACOBSEN NE, FAIRBROTHER WJ, KENSIL CR et al:Struc-ture of the saponin adjuvant QS-21 and its base-catalyzedisomerizationproductby111andnaturalabundance13CNMRspectroscopy.Carbohydr. Res.(1996) 280(0:1–14.
   Google Scholar
• KENSIL CR, SOLTYSIK S, WHEELER DA, WU JY: Struc-ture/function studies on QS-21, a unique immunologi-caladjuvantfromQuillajasaponaria.Adv. Exp. Med. Biol.(1996) 404:165–172.
   PubMedGoogle Scholar
• PILLION DJ, RECCHIA J, WANG P, MARCIANI DJ, KENSIL CR: DS-1,amodifiedQuillajasaponin,enhancesocularandnasalabsorptionofinsulin.J. Pharm. Sci.(1995) 84(10:1276–1279.
   Google Scholar
• SOLTYSIK S, WU JY, RECCHIA J et al:Structure/functionstudies of QS-21 adjuvant: assessment of triterpene al-dehyde and glucuronic acid roles in adjuvant function. Vaccine(1995) 13(15):1403–1410.
   PubMed Web of Science ®Google Scholar
• STOUTE JA, SLAOUI M, HEPPNER DG et al:Apreliminaryevaluation of a recombinant circumsporozoite protein vaccineagainstPlasmodiumfalciparummalaria.New Engl. J. Med.(1997) 9:86–91.
   Web of Science ®Google Scholar
• KENSIL CR, NEWMAN MJ, COUGHLIN RT et al.:TheuseofStimulonadjuvanttoboostvaccineresponse.Vaccine Res.(1993) 2(4):273–281.
   Google Scholar
• CLELAND JL, POWELL MF, LIM A et al.:Developmentofasingle-shotsubunitvaccinefor11IV-1.AIDS Res. Hum. Retroviruses(1994) 10 (Suppl. 2):21–26.
   Google Scholar
• HANCOCK GE, SPEELMAN DJ, FRENCHICK PJ et al.:For-mulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protec-tive immune responses in Balb/c mice that are similar tothosegeneratedbyexperimentalinfection.Vaccine(1995) 13(4):391–400.
   PubMed Web of Science ®Google Scholar
• POWELL MF, EASTMAN DJ, LIM A et al.:Effectofadju-vants on immunogenicity of MN recombinant glyco-protein120inguineapigs.AIDS Res. Hum. Retroviruses(1995) 11 (2):203–209.
   Google Scholar
• POWELL MF, CLELAND JL, EASTMAN DJ et al.:Immuno-genicity and 11IV-1 virus neutralization of MN recombi-nant glycoprotein 120/HIV-1 Q521 vaccine in baboons.AIDS Res. Hum. Retroviruses(1994) 10\(Suppl. 2) :105–108.
   Google Scholar
• COUGHLIN RT, FATTOM A, CHU C, WHITE AC, WINSTONS: AdjuvantactivityofQS-21forexperimentalE.coli018polysaccharidevaccines.Vaccine(1995) 13(1):17–21.
   Google Scholar
• WU JY, GARDNER BH, MURPHY CI et al:Saponinadju-vant enhancement of antigen-specific immune re-sponsestoanexperimental11IV-1vaccine.J. Immunol(1992) 148(5):1519–1525.
   Google Scholar
• NEWMAN MJ, WU JY, GARDNER BH et al:Saponinadju-vantinductionofovalbumin-specificCD8+cytotoxicTlymphocyteresponses.J. Immunol.(1992) 148(8):2357–2362.
   Google Scholar
• ••First report of capacity of QS-21 to enhance cell-mediatedimmune responses.
   Google Scholar
• BRITT W, FAY J, SEALS J, KENSIL C: Formulationofanim-munogenic human cytomegalovirus vaccine: re-sponsesinmice.J. Infect. Dis.(1995) 171(1):18–25.
   Google Scholar
• FENTON RG, KELLER CJ, HANNA N, TAUB DD: Inductionof T-cell immunity against Ras oncoproteins by solu-bleproteinorRas-expressingEscherichiacolt'.J. Natl. Cancer Inst.(1995) 87(201853-1861.
   Google Scholar
• LIVINGSTON PO, ADLURI S, HELLING F etal.:PhaseItrialof immunological adjuvant QS-21 with a GM2 ganglio-side - keyhole limpet haemocyanin conjugate vaccine inpatientswithmalignantmelanoma.Vaccine(1994) 12(101275–1280.
   Google Scholar
• KEEFER MC, WOLFF M, GORSE GJ et al.:SafetyprofileofPhase I and II preventive HIV type 1 envelope vaccina-tion: experience of the NIAID AIDS Vaccine Evaluation Group.AIDS Res. Hum. Retroviruses(1997) 13(14): 1163–1177.
   Google Scholar
• HELLING F, ZHANG S, SHANG A et al.:GM2-KLHconju-gate vaccine: increased immunogenicity in melanoma patients after administration with immunological ad-juvantQS-21.Cancer Res.(1995) 55(13)2783–2788.
   Google Scholar
• ••A report on the first clinical trial of a vaccine using QS-21.
   Google Scholar
• LIVINGSTON PO, ADLURI S, ZHANG S etalImpactofim- munological adjuvants and administration route on HAMA response after immunization with murine © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs(1998) 7(9) monoclonal antibody MELIMMUNE-1 in melanoma pa-tients.Vaccine Res.(1995) 4(2)87–94.
   Google Scholar
• MCCAFFERY M, YAO TJ, WILLIAMS L et al.:Immunizationof melanoma patients with BEC2 anti-idiotypic mono-clonal antibody that mimics GD3 ganglioside: en-hanced immunogenicity when combined with adjuvant.Clin. Cancer Res.(1996) 2:679–686.
   Google Scholar
• FOON KA, SEN G, HUTCHINS L et al:Antibodyre-sponses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.Clin. Cancer Res.(1998) 4(5):1117–1124.
   Google Scholar